Relapsed Or Refractory Large B Cell Lymphoma R R Lbcl clinical trials

Explore recruiting relapsed or refractory large b cell lymphoma r r lbcl clinical trials.

Recruiting relapsed or refractory large b cell lymphoma r r lbcl studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Large B Cell Lymphoma R R Lbcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants with Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Belgium, Germany, Poland, Czechia, Netherlands, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Or Refractory Large B Cell Lymphoma R R Lbcl trials by city

Relapsed Or Refractory Large B Cell Lymphoma R R Lbcl clinical trials

Recruiting relapsed or refractory large b cell lymphoma r r lbcl studies right now

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Also recruiting in Europe

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants with Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Relapsed Or Refractory Large B Cell Lymphoma R R Lbcl trials by city

Other conditions